Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2010
06/17/2010WO2010068308A1 Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease
06/17/2010WO2010068296A1 Piperazine carboxamidines as antimicrobial agents
06/17/2010WO2010068292A1 Azaindole derivatives as kinase inhibitors
06/17/2010WO2010068287A2 Small molecule modulators of hepatocyte growth factor (scatter factor) activity
06/17/2010WO2010068281A2 Contact lens drug delivery device
06/17/2010WO2010068275A1 Silica-based antibacterial and antifungal nanoformulation
06/17/2010WO2010068258A1 Imidazopyrazine syk inhibitors
06/17/2010WO2010068257A1 Imidazopyrazine syk inhibitors
06/17/2010WO2010068253A1 Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
06/17/2010WO2010068242A1 Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
06/17/2010WO2010068238A1 Hypoxia targeted compounds for cancer diagnosis and therapy
06/17/2010WO2010068183A1 Glucose-peg conjugates for reducing glucose transport into a cell
06/17/2010WO2010068182A1 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene maleate salt
06/17/2010WO2010068181A1 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt
06/17/2010WO2010068173A1 L-lysine for improving normal cognitive functions
06/17/2010WO2010068130A1 Agent for treating oncological diseases using the isotope calcium-41
06/17/2010WO2010068056A2 Composition containing glucosamine or glucosamine derivative for preventing or treating hemadostenosis and restenosis
06/17/2010WO2010068037A2 Anti-cancer composition containing 4-hexylresorcinol-1,3-diol as active ingredient
06/17/2010WO2010067986A2 Composition for controlling gastrointestinal tract movement
06/17/2010WO2010067980A2 Histone deacetylase inhibitor that reactivates hiv-1 proviruses from latently hiv-infected cells
06/17/2010WO2010067900A1 Risk assessment for cutaneous adverse drug reactions from antiretroviral agent
06/17/2010WO2010067888A1 Dihydropyrimidopyrimidine derivatives
06/17/2010WO2010067886A1 Dihydropyrimidopyrimidine derivative
06/17/2010WO2010067883A1 Feed for preventing and/or treating diseases due to clostridium sp. bacteria in livestock, and anti-clostridium agent
06/17/2010WO2010067869A1 Anti-viral agent and anti-viral composition
06/17/2010WO2010067617A1 Lipid membrane structure
06/17/2010WO2010067594A1 Hexahydropyrroloindole derivative
06/17/2010WO2010067487A1 Nectin-4 for target genes of cancer therapy and diagnosis
06/17/2010WO2010067335A1 Platinum (iv) complexes for use in the treatment of proliferative diseases such as cancer
06/17/2010WO2010067332A1 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives
06/17/2010WO2010067233A1 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
06/17/2010WO2010067206A1 Lipid composition for the treatment of skin problems in companion animals
06/17/2010WO2010067204A1 Highly pure cinacalcet or a pharmaceutically acceptable salt thereof
06/17/2010WO2010067140A1 Pulsed-release sildenafil composition and method for preparing said composition
06/17/2010WO2010067136A1 Novel crystalline forms
06/17/2010WO2010067130A1 P38 map kinase inhibitors
06/17/2010WO2010067125A1 2- (piperidin-1-yl) -4-azolyl-thiazole-5-carboxylic acid derivatives against bacterial infections
06/17/2010WO2010067123A1 2- (piperidin-1-yl) -4-heterocyclyl-thiazole-5-carboxylic acid derivatives against bacterial infections
06/17/2010WO2010067102A1 Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
06/17/2010WO2010067101A1 Dihydroetorphines and their preparation
06/17/2010WO2010067072A1 Rifaximin complexes
06/17/2010WO2010067069A1 Compounds for use in the treatment of pain
06/17/2010WO2010067067A1 Compounds for treating cancer
06/17/2010WO2010067036A1 Novel aryl c-xyloside compounds, and cosmetic use
06/17/2010WO2010067027A1 Antitumor combination combining ave8062 and docetaxel
06/17/2010WO2010067010A2 Derivatives of morphine-6-glucuronide, preparation method thereof and use of same in therapeutics
06/17/2010WO2010067008A2 Bicyclic derivatives of morphine-6-glucuronide, preparation method thereof and use of same in therapeutics
06/17/2010WO2010067007A2 Synthesis of morphine-6-glucuronide or one of the derivatives thereof
06/17/2010WO2010066933A1 Use of cyclosquaramide compounds as anti-tumour agents
06/17/2010WO2010066931A1 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
06/17/2010WO2010066912A2 Compounds having activity in correcting mutant cftr cellular processing
06/17/2010WO2010066909A2 New inhibitors for treating diseases associated with an excess transport of hyaluronan
06/17/2010WO2010066901A2 Tetrahydrotriazine compounds for treating diseases associated with ampk activity
06/17/2010WO2010066883A1 A method for contraception
06/17/2010WO2010066858A1 Methods for the treatment and the prognosis of cancer
06/17/2010WO2010066852A1 Composition comprising isoflavones
06/17/2010WO2010066847A1 Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-hiv agents
06/17/2010WO2010066840A1 SPIRO AZEPANE-OXAZOLIDINONES AS Kv1.3 POTASSIUM CHANNEL BLOCKERS
06/17/2010WO2010066832A1 Triple substituted phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases or conditions, or cancer
06/17/2010WO2010066815A2 Encapsulating system for cest imaging with chelate q greater than or equal to 2
06/17/2010WO2010066810A1 Transdermal pharmaceutical compositions comprising a serm
06/17/2010WO2010066756A1 Polymorph ii of an antifungal compound
06/17/2010WO2010066749A2 Ulipristal acetate tablets
06/17/2010WO2010066709A1 Novel pyridinyl acrylamide derivatives
06/17/2010WO2010066699A1 Uracyl cyclopropyl nucleotides
06/17/2010WO2010066690A1 A novel crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
06/17/2010WO2010066689A2 Organic compounds
06/17/2010WO2010066687A2 Stabalized statin-comprising compositions
06/17/2010WO2010066684A2 Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease
06/17/2010WO2010066682A1 Compounds, pharmaceutical composition and methods for use in treating metabolic disorders
06/17/2010WO2010066658A1 Compounds which potentiate the ampa receptor and uses thereof in medicine
06/17/2010WO2010066641A1 Oral composition
06/17/2010WO2010066629A2 Novel azaindoles
06/17/2010WO2010066593A1 Combined drug administration
06/17/2010WO2010066437A2 Aqueous composition containing dexpanthenol and sodium chloride
06/17/2010WO2010066385A1 Compacted moxifloxacin
06/17/2010WO2010066384A1 Compositions and methods for micro-rna expression profiling of cancer stem cells
06/17/2010WO2010066380A1 Triaryl-sulphonium compounds, kit and methods for labeling positron emitting isotopes
06/17/2010WO2010066357A1 Benzothiazole amides for detection of amyloid beta
06/17/2010WO2010066355A1 USE OF 17β-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVES FOR MANUFACTURING A MEDICAMENT IN A SUSTAINED-RELEASE FORM FOR PARENTERAL USE, AND SUSTAINED-RELEASE MEDICAMENT CONTAINING 17β-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVES FOR PARENTERAL USE
06/17/2010WO2010066354A1 USE OF 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVES FOR MANUFACTURING A MEDICAMENT IN A SUSTAINED-RELEASE FORM FOR PARENTERAL USE, AND SUSTAINED-RELEASE MEDICAMENT CONTAINING 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVES FOR PARENTERAL USE
06/17/2010WO2010066349A1 Use of 17beta-cyano-19-androst-4-ene derivatives for manufacturing a medicament in a sustained-release form for parenteral use, and sustained-release medicament containing 17beta-cyano-19-androst-4-ene derivatives for parenteral use
06/17/2010WO2010066342A1 Quetiapine composition
06/17/2010WO2010066326A1 Combination of insulin with triazine derivatives and its use for treating diabetes
06/17/2010WO2010066268A1 Tamsulosin pellets for fixed dose combination
06/17/2010WO2010066253A1 Selective inhibitors of excitatory amino acid transporter subtype 1 (eaat1 /glast)
06/17/2010WO2010066239A1 Inhibitors of dimethylarginine dimethylaminohydrolase
06/17/2010WO2010066199A1 Use of racemates of pinocembrin in preparing medicaments for treating stroke
06/17/2010WO2010066159A1 A preparation method of venlafaxine sustained release formulation
06/17/2010WO2010066111A1 Phenyl pyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof
06/17/2010WO2010066100A1 The 2-oxo-1,3-oxaazocyclopentane-4-formamide derivatives and their uses as the immunosuppressant.
06/17/2010WO2010066075A1 The use of hylotelephin in preparing medicaments for treating hbeag positive chronic hepatitis b in human
06/17/2010WO2010066046A1 Proliferation-associated modulation of the splicing of the integrin alpha 6 isoforms
06/17/2010WO2010066034A1 Methadone formulation
06/17/2010WO2010066028A1 3,4 - substituted piperidine derivatives as renin inhibitors
06/17/2010WO2010066018A1 Novel human endogenous retorviral erv3 variant and uses thereof for diagnosing ovarian cancer
06/17/2010WO2010066010A1 Process for the preparation of asymmetrical bis(thiosemicarbazones)
06/17/2010WO2010065995A1 Isolated vegf-c and vegf-d peptides and uses thereof
06/17/2010WO2010049915A8 Poly-heteroaryl derivatives for the treatment of cancer
06/17/2010WO2010048352A3 Methods for treating eye disorders
1 ... 2214 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 ... 7860